Citigroup Inc Tricida, Inc. Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	BUY	$0.14 - $12.49 $5,205 - $464,403	37,182 Added 2107.82%	38,946 $5,000
Q3 2022 Nov 10, 2022	SELL	$8.51 - $13.6 $14,662 - $23,432	-1,723 Reduced 49.41%	1,764 $18,000
Q2 2022 Aug 10, 2022	SELL	$7.31 - $11.85 $680,517 - $1.1 Million	-93,094 Reduced 96.39%	3,487 $34,000
Q1 2022 May 12, 2022	BUY	$7.35 - $10.63 $415,708 - $601,222	56,559 Added 141.32%	96,581 $794,000
Q4 2021 Feb 10, 2022	BUY	$4.19 - $9.56 $151,485 - $345,632	36,154 Added 934.69%	40,022 $383,000
Q3 2021 Nov 10, 2021	BUY	$3.56 - $4.64 $13,770 - $17,947	3,868 New	3,868 $18,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.